- Home
- LCTX vs MHN Comparison
LCTX vs MHN Comparison
Compare LCTX & MHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- MHN
- Stock Information
- Founded
- LCTX 1990
- MHN 1997
- Country
- LCTX United States
- MHN United States
- Employees
- LCTX N/A
- MHN N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- MHN Investment Bankers/Brokers/Service
- Sector
- LCTX Health Care
- MHN Finance
- Exchange
- LCTX Nasdaq
- MHN Nasdaq
- Market Cap
- LCTX 274.0M
- MHN 293.6M
- IPO Year
- LCTX N/A
- MHN N/A
- Fundamental
- Price
- LCTX $1.44
- MHN $10.21
- Analyst Decision
- LCTX Strong Buy
- MHN
- Analyst Count
- LCTX 4
- MHN 0
- Target Price
- LCTX $4.25
- MHN N/A
- AVG Volume (30 Days)
- LCTX 1.2M
- MHN 59.2K
- Earning Date
- LCTX 11-13-2025
- MHN 01-01-0001
- Dividend Yield
- LCTX N/A
- MHN 4.17%
- EPS Growth
- LCTX N/A
- MHN N/A
- EPS
- LCTX N/A
- MHN N/A
- Revenue
- LCTX $10,914,000.00
- MHN N/A
- Revenue This Year
- LCTX N/A
- MHN N/A
- Revenue Next Year
- LCTX $176.00
- MHN N/A
- P/E Ratio
- LCTX N/A
- MHN N/A
- Revenue Growth
- LCTX 76.43
- MHN N/A
- 52 Week Low
- LCTX $0.37
- MHN $8.69
- 52 Week High
- LCTX $1.42
- MHN $10.81
- Technical
- Relative Strength Index (RSI)
- LCTX 69.73
- MHN 72.35
- Support Level
- LCTX $1.20
- MHN $10.08
- Resistance Level
- LCTX $1.42
- MHN $10.27
- Average True Range (ATR)
- LCTX 0.07
- MHN 0.10
- MACD
- LCTX 0.01
- MHN 0.05
- Stochastic Oscillator
- LCTX 91.67
- MHN 93.33
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About MHN Blackrock MuniHoldings New York Quality Fund Inc.
BLACKROCK MUNIHOLDINGS NEW YORK QUALITY FUND, INC. is a closed-ended management investment company. The fund's investment objective is to provide shareholders with current income exempt from federal income tax and New York State and New York City personal income taxes.